News

The multicenter randomized double-blind placebo-controlled Phase III studies evaluated Suvorexant compared to placebo in adult patients aged 18 years and older. In the trials, the primary endpoint was

The company plans to launch the product in Austria after completion of the national pricing and reimbursement process. Almirall, GW’s marketing partner, will market Sativex in Austria. In

The recall of Ofirmev lot number V005710 was initiated due to the presence of an unidentified, visible particle in one vial of this lot during routine stability testing.

The agreement includes milestones, upfront license fees and royalties payable to both the companies. The terms of the agreement are consistent with BioLineRx’s standard in-license agreements. BL-8030 is

As per the agreement, Eurofins STA will gain non-exclusive rights to a number of GTG patents relating to its non-coding DNA technology. The precise commercial terms of the

The randomized study is designed to test whether remote health monitoring is feasible in patients with moderate-severe COPD, improves treatment adherence, symptoms, activity level and quality of life.

The aim of the partnership is to identify and develop compounds that are safe and effective against VL parasites. The collaboration underlines the relative experience and expertise of

Acorda will receive a royalty from Watson based on product sales. Additional terms of the agreement have not been disclosed. Tizanidine hydrochloride capsule is a short-acting drug indicated

Synchroneuron co-founder and CSO Fogel said they aim to bring relief to millions of patients with TD and other movement disorders by developing novel therapies. The company plans